Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

Please add ResearchGrants@BrightFocus.org to your institution’s white list to insure that the notification is not blocked by your organization’s SPAM filters.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

 
 
BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

Alzheimer's Disease Research
Completed Award

Dr. Jason E. Gestwicki

Jason E. Gestwicki, Ph.D.

University of California, San Diego
San Diego, CA, United States

Title: Chemical Approaches to Reducing Tau Levels
Non-Technical Title: Lowering Tau in the Brain

Co-PI(s):
Chad Dickey, Ph.D.
University of South Florida

Duration: July 1, 2012 - September 30, 2014
Award Type: Standard
Award Amount: $150,000

Summary:

Tau is a protein that aberrantly accumulates in the brains of patients with Alzheimer's disease. The goal of this proposal by Drs. Jason E. Gestwicki, Chad Dickey, and colleagues is to determine whether newly discovered chemical inhibitors of heat shock protein 70 (Hsp70) will reduce tau accumulation. Such compounds are expected to be potential therapeutics with an under-explored mechanism.

Details:

The goal of this project is to test whether heat shock protein 70 (Hsp70) might be a new, under-explored drug target for Alzheimer's disease (AD). Hsp70 has been linked to AD because it is able to counteract the accumulation of a protein, tau, which is commonly observed in AD patients. However, no drug-like chemicals have been available that bind to Hsp70, so it hasn't been clear whether it could be a new therapeutic target.

Dr. Jason E. Gestwicki and his team recently uncovered a promising class of Hsp70-binding compounds and have shown that these compounds reduce tau accumulation in cellular and animal models of AD. The next major goal is to improve the safety and efficacy of these compounds before they are tested in human clinical trials.

These studies are designed to establish whether Hsp70 is a bona fide drug target for AD. The goal of this project is to produce a set of pre-clinical data that could, if successful, provide the rationale for advancing these compounds towards clinical trials.

Investigator Biography:

As of April 1, 2013, Dr. Gestwicki is the Associate Professor in the In Residence series at the Institute for Neurodegenerative Diseases (IND) and the Department of Pharmaceutical Chemistry at UCSF (formerly the William B. Pratt Collegiate Professor of the Life Sciences Institute and Associate Professor of Pathology and Biological Chemistry at the University of Michigan). He completed doctoral studies at University of Wisconsin and post-doctoral work at Stanford University. Dr. Gestwicki's laboratory uses the tools of organic chemistry to explore how molecular chaperones regulate protein misfolding and accumulation in neurodegenerative disorders. In addition to a BrightFocus award, Dr. Gestwicki has been funded by the National Institutes of Health and the National Science Foundation.

Dr. Gestwicki is originally from western New York State and completed undergraduate studies in chemistry at the State University of New York College at Fredonia. He started his independent research group at the University of Michigan in 2005 and is focused on finding new ways of treating Alzheimer's disease.